These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 22275388)

  • 1. A comparison of the pharmacodynamic behavior of branded and biosimilar enoxaparin in primates.
    Jeske W; Litinas E; Khan H; Hoppensteadt D; Fareed J
    Clin Appl Thromb Hemost; 2012 Jun; 18(3):294-8. PubMed ID: 22275388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative studies on branded enoxaparin and a US generic version of enoxaparin.
    Walenga JM; Jeske WP; Hoppensteadt D; Cunanan J; Khan H; Escalante V; Fareed J; Bakhos M
    Clin Appl Thromb Hemost; 2013 Jun; 19(3):261-7. PubMed ID: 23091283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
    Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
    J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative studies on biological activity of generic and branded enoxaparin in vivo and vitro.
    Tan X; Cui H
    Blood Coagul Fibrinolysis; 2015 Oct; 26(7):805-10. PubMed ID: 26270263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the antithrombotic fingerprint of the branded and copies of the low-molecular-weight enoxaparin using thrombin generation assay.
    Gerotziafas GT; Rouseau A; Mbemba E; Khartechi A; Van Dreden P; Walenga J; Fareed J; Elalamy I
    Clin Appl Thromb Hemost; 2015 Nov; 21(8):697-704. PubMed ID: 26023170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Studies on the Anticoagulant Profile of Branded Enoxaparin and a New Biosimilar Version.
    Qneibi D; Ramacciotti E; Macedo AS; Caffaro RA; Agati LB; Siddiqui F; Kouta A; Hoppensteadt D; Fareed J; Carter CA
    Clin Appl Thromb Hemost; 2020; 26():1076029620960820. PubMed ID: 32996340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboelastographic evaluation of blood coagulation in the presence of branded and generic enoxaparins.
    Walenga JM; Jeske WP; Escalante V; Hoppensteadt D; Fareed J; Bakhos M
    Int Angiol; 2012 Dec; 31(6):517-25. PubMed ID: 23222929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D; Dawes J
    Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers.
    Antonijoan RM; Rico S; Martínez-González J; Borrell M; Valcarcel D; Fontcuberta J; Barbanoj MJ
    Int J Clin Pharmacol Ther; 2009 Dec; 47(12):726-32. PubMed ID: 19954711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.
    Azizi M; Veyssier-Belot C; Alhenc-Gelas M; Chatellier G; Billaud-Mesguish E; Fiessinger JN; Aiach M
    Br J Clin Pharmacol; 1995 Dec; 40(6):577-84. PubMed ID: 8703665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Pharmacokinetic Profile of 3 Batches of Ovine Low-Molecular-Weight Heparin and 1 Batch of Branded Enoxaparin.
    Jeske W; Kouta A; Duff R; Rangnekar V; Niverthi M; Hoppensteadt D; Fareed J; Yao Y
    Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):150S-156S. PubMed ID: 30198315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The United States Food and Drugs Administration approves a generic enoxaparin.
    Ofosu FA
    Clin Appl Thromb Hemost; 2011 Feb; 17(1):5-8. PubMed ID: 21159709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).
    Collignon F; Frydman A; Caplain H; Ozoux ML; Le Roux Y; Bouthier J; Thébault JJ
    Thromb Haemost; 1995 Apr; 73(4):630-40. PubMed ID: 7495071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
    Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
    Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers.
    Sanderink GJ; Le Liboux A; Jariwala N; Harding N; Ozoux ML; Shukla U; Montay G; Boutouyrie B; Miro A
    Clin Pharmacol Ther; 2002 Sep; 72(3):308-18. PubMed ID: 12235452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of subcutaneous low molecular weight heparin (enoxaparin) in dogs.
    Lunsford KV; Mackin AJ; Langston VC; Brooks M
    J Am Anim Hosp Assoc; 2009; 45(6):261-7. PubMed ID: 19887383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation of generic enoxaparins marketed in the United States by employing NMR and multivariate analysis.
    Guerrini M; Rudd TR; Mauri L; Macchi E; Fareed J; Yates EA; Naggi A; Torri G
    Anal Chem; 2015 Aug; 87(16):8275-83. PubMed ID: 26189325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.